| Date | Title | Description | |
|---|---|---|---|
| 08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download |
| 08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
| 25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
| 27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
| 27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 13 May 2021 | On business and financial situation | ROVI releases the first quarter 2021 results presentation | Download |
| 13 May 2021 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2021 General Shareholders Meeting | Download |
| 13 May 2021 | On business and financial situation | The company releases the press release related to first quarter 2021 financial results | Download |
| 06 Apr 2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2021 | Download |
| 24 Feb 2021 | On business and financial situation | The company releases the press release related to 2020 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |